Alan D. Pierce, MD, FCAP, Joins Aurora Diagnostics as Chief Medical Officer

PALM BEACH GARDENS, FL – Aurora Diagnostics announced today that Alan Pierce, MD, is joining the Company as Chief Medical Officer effective September 1.

“We welcome Dr. Pierce to the new role of Chief Medical Officer of Aurora Diagnostics,” said Daniel D. Crowley, Chief Executive Officer. “Aurora’s mission is to deliver high quality diagnostic results with excellent service, and we are building a physician-centered culture that supports this. As Chief Medical Officer, Dr. Pierce will be at the table with senior management and work with our 21 labs, nearly 130 pathologists and our Medical Advisory Committees to set medical policy, develop new diagnostic services to support growth, evaluate new technologies, determine best practices, and create the gold standard for pathology in America.”

“I am excited to join Aurora’s dynamic organization,” said Dr. Pierce. “Challenges and opportunities in diagnostic medicine have never been greater.  Aurora is clearly committed to leading the industry with innovative strategies while retaining the highest quality of pathology service.  As the nation’s largest independent pathology lab company Aurora is positioned to continue its growth supported by a strong commitment to physician involvement.”

Dr. Pierce is a practicing pathologist. He is Medical Laboratory Director and Chief of Pathology at Wellington Regional Medical Center in Palm Beach County, Florida; Consultant Pathologist at Aiken Regional Medical Center, Aiken, South Carolina; President and Laboratory Director of the Meditrend Group, a reference laboratory for anatomic pathology; and Associate Medical Director of Nationwide Laboratory Services.  Dr. Pierce previously served as Medical Laboratory Director and Chief of Pathology at Westside Regional Medical Center, Plantation, Florida and chaired the national Pathology Advisory Committee for Columbia/HCA.  He also served as medical director and scientific advisor to Biosignia, a statistics-based health and disease forecasting company.

Dr. Pierce has a Bachelor of Science degree from the Ohio State University and an MD from St. Louis University.   As a Fellow of the College of American Pathologists, Dr. Pierce chaired and served on many committees, councils and task forces in the areas of physician education, laboratory practice, laboratory management, public affairs, public communication, and primary care services. He serves as an inspector in the Laboratory Accreditation Program.

Dr. Pierce has been active in the American Society of Clinical Pathologists, the Florida Society of Pathologists, the American Medical Association, the Florida Medical Association and the Broward County Medical Association.  His participation in community affairs includes serving as an advisor to Gilda’s Club of Fort Lauderdale.

In addition, Dr. Pierce has agreed to transfer ownership of his laboratory and hospital practice into the Aurora family.

About Aurora Diagnostics

Aurora Diagnostics is the leading independent specialized laboratory company focused on anatomic pathology at 21 locations in the United States. Employing over 130 licensed physicians, Aurora Diagnostics provides high-quality diagnostics and testing information for the patients of its primary referral sources—dermatologists, OB/GYN professionals, gastroenterologists, urologists, general surgeons, oncologists, and for approximately 70 community-based hospitals in 14 states. For additional information regarding Aurora Diagnostics and the services it provides, please visit the company website at www.auroradx.com.

Forward Looking Statements

Certain matters discussed in this press release may constitute forward-looking statements within the meaning of federal securities laws. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors, some of which are not within the control of the Company.  Aurora reports information that may be significant for investors in its filings with the Securities and Exchange Commission (SEC), and Aurora encourages investors to consult those filings.